Literature DB >> 8943748

Mycobacterium kansasii: its presentation, treatment and outcome in HIV infected patients.

G Rooney1, M R Nelson, B Gazzard.   

Abstract

AIM: To report the clinical significance and treatment of Mycobacterium kansasii infection in the context of HIV disease. DESIGN/
METHODS: Retrospective case review of all isolates of M kansasii until June 1994.
RESULTS: Ten cases of M kansasii were isolated. All but one patient with this infection had clinical symptoms compatible with generalised infection. The majority had chest infections with the organism isolated on induced sputum but not routine sputum. All isolates were sensitive to ethambutol and nine of 10 to rifampicin. All isolates were resistant to isoniazid and pyrazinamide.
CONCLUSION: M kansasii is a pathogen in HIV infected patients and should be treated when isolated. Treatment should be with rifampicin and ethambutol but not isoniazid, as has been recommended previously.

Entities:  

Mesh:

Year:  1996        PMID: 8943748      PMCID: PMC500776          DOI: 10.1136/jcp.49.10.821

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  15 in total

1.  Disseminated Mycobacterium kansasii infection: successful treatment of a patient with pancytopenia.

Authors:  P F Engstrom; G C Dewey; O N Barrett
Journal:  Am J Med       Date:  1972-04       Impact factor: 4.965

2.  The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS).

Authors:  C R Horsburgh; R M Selik
Journal:  Am Rev Respir Dis       Date:  1989-01

3.  Mycobacterium kansasii: a cause of treatable pulmonary disease associated with advanced human immunodeficiency virus (HIV) infection.

Authors:  B Levine; R E Chaisson
Journal:  Ann Intern Med       Date:  1991-05-15       Impact factor: 25.391

4.  Rapid susceptibility testing of Mycobacterium tuberculosis by a radiometric technique.

Authors:  G Vincké; O Yegers; H Vanachter; P A Jenkins; J P Butzler
Journal:  J Antimicrob Chemother       Date:  1982-10       Impact factor: 5.790

5.  Diagnostic criteria for pulmonary disease caused by Mycobacterium kansasii and Mycobacterium intracellulare.

Authors:  C H Ahn; J W McLarty; S S Ahn; S I Ahn; G A Hurst
Journal:  Am Rev Respir Dis       Date:  1982-04

6.  When is an infection disease?

Authors:  E Wolinsky
Journal:  Rev Infect Dis       Date:  1981 Sep-Oct

7.  The spectrum of Mycobacterium kansasii disease associated with HIV-1 infected patients.

Authors:  G T Valainis; L M Cardona; D L Greer
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1991

8.  Sulfonamide-containing regimens for disease caused by rifampin-resistant Mycobacterium kansasii.

Authors:  C H Ahn; R J Wallace; L C Steele; D T Murphy
Journal:  Am Rev Respir Dis       Date:  1987-01

9.  Mycobacterium kansasii among patients infected with human immunodeficiency virus in Kansas City. Kansas City AIDS Research Consortium.

Authors:  D M Bamberger; M R Driks; M R Gupta; M C O'Connor; P M Jost; R E Neihart; D S McKinsey; L A Moore
Journal:  Clin Infect Dis       Date:  1994-03       Impact factor: 9.079

10.  Mycobacterium avium complex infections in patients with the acquired immunodeficiency syndrome.

Authors:  C C Hawkins; J W Gold; E Whimbey; T E Kiehn; P Brannon; R Cammarata; A E Brown; D Armstrong
Journal:  Ann Intern Med       Date:  1986-08       Impact factor: 25.391

View more
  1 in total

Review 1.  Cavitary pulmonary disease.

Authors:  L Beth Gadkowski; Jason E Stout
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.